These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 29607153)

  • 41. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
    Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
    Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
    Beck KS; Kim SJ; Kang JH; Han DH; Jung JI; Lee KY
    Thorac Cancer; 2019 Jul; 10(7):1612-1618. PubMed ID: 31237079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.
    Soo RA; Yun Lim JS; Asuncion BR; Fazreen Z; Herrera MC; Mohd Omar MF; Diem Phuong NH; Seet JE; Amanuel B; Iacopetta B; Byrne D; Hendry S; Fox S; Soong R
    Oncotarget; 2018 Jan; 9(6):6841-6851. PubMed ID: 29467933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
    Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W
    Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation.
    Lee KS; Choe G
    J Pathol Transl Med; 2021 May; 55(3):163-170. PubMed ID: 33823566
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
    Song SG; Lee J; Koh J; Kim S; Chung DH; Jeon YK
    Diagn Cytopathol; 2020 Apr; 48(4):291-299. PubMed ID: 31930724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma.
    Huang TH; Cheng W; Wang YH
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33807802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
    Pak MG; Roh MS
    Cytopathology; 2019 Nov; 30(6):578-585. PubMed ID: 31209979
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Revisiting the impact of clinicopathologic characteristics in PD-L1 profile in a large cohort of non-small cell lung cancer.
    Kang Y; Lee SE; Kim CH; Lee YJ
    Transl Lung Cancer Res; 2024 Mar; 13(3):475-490. PubMed ID: 38601456
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling.
    Kintsler S; Cassataro MA; Drosch M; Holenya P; Knuechel R; Braunschweig T
    Ann Diagn Pathol; 2019 Aug; 41():24-37. PubMed ID: 31132649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
    Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
    Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC.
    Williams GH; Nicholson AG; Snead DRJ; Thunnissen E; Lantuejoul S; Cane P; Kerr KM; Loddo M; Scott MLJ; Scorer PW; Barker C
    J Thorac Oncol; 2020 Apr; 15(4):550-555. PubMed ID: 31778799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
    Pan B; Kang Y; Jin Y; Yang L; Zheng Y; Cui L; Sun J; Feng J; Li Y; Guo L; Liang Z
    J Transl Med; 2021 Jun; 19(1):249. PubMed ID: 34098964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
    Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
    [No Abstract]   [Full Text] [Related]  

  • 57. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
    JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
    Hodgson A; Slodkowska E; Jungbluth A; Liu SK; Vesprini D; Enepekides D; Higgins K; Katabi N; Xu B; Downes MR
    Am J Surg Pathol; 2018 Aug; 42(8):1059-1066. PubMed ID: 29750666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
    Sommer U; Eckstein M; Ammann J; Braunschweig T; Macher-Göppinger S; Schwamborn K; Hieke-Schulz S; Harlow G; Flores M; Wullich B; Wirth M; Roth W; Knüchel R; Weichert W; Baretton G; Hartmann A
    Clin Genitourin Cancer; 2020 Oct; 18(5):e629-e642. PubMed ID: 32178978
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
    Chauhan A; Siegel L; Freese R; Racila E; Stewart J; Amin K
    Diagn Cytopathol; 2021 Mar; 49(3):355-362. PubMed ID: 33142053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.